Celldex Therapeutics, Inc.
CLDXNASDAQHealthcare● Active
$28.55
$-0.07(-0.23%)
Market Cap$1.9B
P/E Ratio—
52W High$35.79
52W Low$19.25
Celldex Therapeutics, Inc. (CLDX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CLDX · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$1.18
Est. -$1.15 · -2.9%
Revenue
$0.00B
Est. $0.00B · -98.1%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
CLDX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$1.08 | — | — | — | $0.00B | — |
| ▼ Q2 FY2026 | May 7, 2026 | -$1.15 | -$1.18 | -2.9% | $0.00B | $0.00B | -98.1% |
| ▼ Q1 FY2026 | Feb 25, 2026 | -$1.00 | -$1.22 | -22.0% | $0.00B | $0.00B | -92.4% |
| ▼ Q4 FY2025 | Nov 10, 2025 | -$0.88 | -$1.01 | -14.8% | — | $0.00B | — |
| ▲ Q3 FY2025 | Aug 7, 2025 | -$0.86 | -$0.85 | +1.2% | $0.00B | $0.00B | -38.3% |
| ▼ Q2 FY2025 | May 8, 2025 | -$0.75 | -$0.81 | -8.0% | $0.00B | $0.00B | -38.0% |
| ▲ Q1 FY2025 | Feb 27, 2025 | -$0.73 | -$0.71 | +2.7% | $0.00B | $0.00B | -6.2% |
| ▲ Q4 FY2024 | Nov 6, 2024 | -$0.69 | -$0.64 | +7.3% | $0.00B | $0.00B | +192.8% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$1.08
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Miss
EPS Actual
-$1.18
EPS Est.
-$1.15
EPS Surpr.
-2.9%
Revenue
$0.00B
Q1 FY2026
Feb 25, 2026Miss
EPS Actual
-$1.22
EPS Est.
-$1.00
EPS Surpr.
-22.0%
Revenue
$0.00B
Q4 FY2025
Nov 10, 2025Miss
EPS Actual
-$1.01
EPS Est.
-$0.88
EPS Surpr.
-14.8%
Revenue
—
Q3 FY2025
Aug 7, 2025Beat
EPS Actual
-$0.85
EPS Est.
-$0.86
EPS Surpr.
+1.2%
Revenue
$0.00B
Q2 FY2025
May 8, 2025Miss
EPS Actual
-$0.81
EPS Est.
-$0.75
EPS Surpr.
-8.0%
Revenue
$0.00B
Q1 FY2025
Feb 27, 2025Beat
EPS Actual
-$0.71
EPS Est.
-$0.73
EPS Surpr.
+2.7%
Revenue
$0.00B
Q4 FY2024
Nov 6, 2024Beat
EPS Actual
-$0.64
EPS Est.
-$0.69
EPS Surpr.
+7.3%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-2.00 | $-1.11 | $-0.23 | 2 |
| Q3 FY2027 | $-1.86 | $-1.03 | $-0.21 | 2 |
| Q2 FY2027 | $-1.74 | $-0.97 | $-0.20 | 2 |
| Q1 FY2027 | $-1.71 | $-0.95 | $-0.19 | 2 |
| Q4 FY2026 | $-1.91 | $-1.06 | $-0.22 | 4 |
| Q3 FY2026 | $-1.12 | $-1.07 | $-1.04 | 6 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 5 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 6 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 7, 2026 | -2.9% | $34.39 | $33.32 | -3.11% |
| ▼ Q1 FY2026 | Feb 25, 2026 | -22.0% | $24.84 | $30.82 | +24.07% |
| ▼ Q4 FY2025 | Nov 10, 2025 | -14.8% | $22.90 | $22.67 | -1.00% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +1.2% | $21.44 | $21.21 | -1.07% |
| ▼ Q2 FY2025 | May 8, 2025 | -8.0% | $18.91 | $19.52 | +3.23% |
| ▲ Q1 FY2025 | Feb 27, 2025 | +2.7% | $20.63 | $20.31 | -1.55% |
| ▲ Q4 FY2024 | Nov 6, 2024 | +7.3% | $25.43 | $27.63 | +8.65% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +8.5% | $32.06 | $32.71 | +2.03% |
Q2 FY2026-3.11%
Report Date
May 7, 2026
EPS Beat/Miss
-2.9%
Price Before
$34.39
Price After
$33.32
Q1 FY2026+24.07%
Report Date
Feb 25, 2026
EPS Beat/Miss
-22.0%
Price Before
$24.84
Price After
$30.82
Q4 FY2025-1.00%
Report Date
Nov 10, 2025
EPS Beat/Miss
-14.8%
Price Before
$22.90
Price After
$22.67
Q3 FY2025-1.07%
Report Date
Aug 7, 2025
EPS Beat/Miss
+1.2%
Price Before
$21.44
Price After
$21.21
Q2 FY2025+3.23%
Report Date
May 8, 2025
EPS Beat/Miss
-8.0%
Price Before
$18.91
Price After
$19.52
Q1 FY2025-1.55%
Report Date
Feb 27, 2025
EPS Beat/Miss
+2.7%
Price Before
$20.63
Price After
$20.31
Q4 FY2024+8.65%
Report Date
Nov 6, 2024
EPS Beat/Miss
+7.3%
Price Before
$25.43
Price After
$27.63
Q3 FY2024+2.03%
Report Date
Aug 8, 2024
EPS Beat/Miss
+8.5%
Price Before
$32.06
Price After
$32.71
Avg Beat Reaction+2.02%
Avg Miss Reaction+5.80%
Beat Rate4 / 8 quarters
Largest Move+24.07% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CLDX ends December
Celldex Therapeutics, Inc. (CLDX) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-1.18 — missing the analyst consensus of $-1.15 by -2.9%. The next CLDX earnings date is expected around September 1, 2026.
Each quarter, investors track CLDX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CLDX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CLDX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CLDX earnings · 5 questionsCelldex Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. CLDX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CLDX historically reports after market close (AMC).
CLDX earnings datewhen is CLDX earningsCLDX next earnings datewhen does CLDX report earningsCLDX earnings calendar
▸ Source: FMP · Celldex Therapeutics, Inc. SEC filings · US GAAP · Celldex Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026